



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 9/19/05

Signature: (Ginny Bundell)

Docket No.: CIBT-P01-058  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Lu et al.

Application No.: 09/499526

Confirmation No.: 1398

Filed: February 10, 2000

Art Unit: 1647

For: METHODS AND REAGENTS FOR  
TREATING GLUCOSE METABOLIC  
DISORDERS

Examiner: R. M. Deberry

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

09/22/2005 ERYALEW1 00000131 181945 09499526  
180.00 DA  
09/23/05 1806

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. CIBT-P01-058. A duplicate copy of this paper is enclosed.

Dated: 9/19/05

Respectfully submitted,

By 

Melissa S. Rones, Ph.D.

Registration No.: 54,408

ROPES & GRAY LLP


One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/17 (12-04v2)  
Approved for use through 7/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.


|   |  |                          |                   |
|---|--|--------------------------|-------------------|
| <b>Effective on 12/08/2004.</b><br><b>Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).</b> |  | <b>Complete if Known</b> |                   |
| <b>FEE TRANSMITTAL</b><br><b>For FY 2005</b>  |  | Application Number       | 09/499526         |
|   |  | Filing Date              | February 10, 2000 |
|   |  | First Named Inventor     | Kuanghui Lu       |
|   |  | Examiner Name            | R. M. Deberry     |
|   |  | Art Unit                 | 1647              |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27                                    |  | Attorney Docket No.      | CIBT-P01-058      |
| <b>TOTAL AMOUNT OF PAYMENT</b>  |  | <b>(\$)</b>              | <b>180.00</b>     |

|   |  |
|---|--|
| <b>METHOD OF PAYMENT</b> (check all that apply)   |  |
| <input type="checkbox"/> Check  | <input type="checkbox"/> Credit Card   |
| <input type="checkbox"/> Money Order  | <input type="checkbox"/> None  |
| <input type="checkbox"/> Other (please identify): _____   |  |
| <input checked="" type="checkbox"/> Deposit Account   | Deposit Account Number: <u>18-1945</u> Deposit Account Name: <u>Ropes &amp; Gray LLP</u> |
| For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)                |  |
| <input checked="" type="checkbox"/> Charge fee(s) indicated below   | <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee        |
| <input checked="" type="checkbox"/> Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17 | <input checked="" type="checkbox"/> Credit any overpayments                              |

|   |                     |   |                      |                                  |                         |                     |                       |
|---|---------------------|---|----------------------|----------------------------------|-------------------------|---------------------|-----------------------|
| <b>FEE CALCULATION</b>  |                     |   |                      |                                  |                         |                     |                       |
| <b>1. BASIC FILING, SEARCH, AND EXAMINATION FEES</b>  |                     |   |                      |                                  |                         |                     |                       |
|   | <b>FILING FEES</b>  |   | <b>SEARCH FEES</b>   |                                  | <b>EXAMINATION FEES</b> |                     |                       |
|   |                     | <b>Small Entity</b>                                     |                      | <b>Small Entity</b>              |                         | <b>Small Entity</b> |                       |
| <b>Application Type</b>   | <b>Fee (\$)</b>     | <b>Fee (\$)</b>   | <b>Fee (\$)</b>      | <b>Fee (\$)</b>                  | <b>Fee (\$)</b>         | <b>Fee (\$)</b>     | <b>Fees Paid (\$)</b> |
| Utility   | 300                 | 150   | 500                  | 250                              | 200                     | 100                 |                       |
| Design  | 200                 | 100   | 100                  | 50                               | 130                     | 65                  |                       |
| Plant   | 200                 | 100   | 300                  | 150                              | 160                     | 80                  |                       |
| Reissue   | 300                 | 150   | 500                  | 250                              | 600                     | 300                 |                       |
| Provisional   | 200                 | 100   | 0                    | 0                                | 0                       | 0                   |                       |
| <b>2. EXCESS CLAIM FEES</b>   |                     |   |                      |                                  |                         |                     |                       |
| <b>Fee Description</b>  |                     |   |                      |                                  |                         | <b>Small Entity</b> |                       |
|   |                     |   |                      |                                  |                         | <b>Fee (\$)</b>     | <b>Fee (\$)</b>       |
| Each claim over 20 (including Reissues)   |                     |   |                      |                                  |                         | 50                  | 25                    |
| Each independent claim over 3 (including Reissues)  |                     |   |                      |                                  |                         | 200                 | 100                   |
| Multiple dependent claims   |                     |   |                      |                                  |                         | 360                 | 180                   |
| <b>Total Claims</b>   | <b>Extra Claims</b> | <b>Fee (\$)</b>   | <b>Fee Paid (\$)</b> | <b>Multiple Dependent Claims</b> |                         | <b>Fee (\$)</b>     | <b>Fee Paid (\$)</b>  |
| <hr/>   |                     |   |                      |                                  |                         |                     |                       |
| <b>Indep. Claims</b>  | <b>Extra Claims</b> | <b>Fee (\$)</b>   | <b>Fee Paid (\$)</b> |                                  |                         |                     |                       |
| <hr/>   |                     |   |                      |                                  |                         |                     |                       |
| <b>3. APPLICATION SIZE FEE</b>  |                     |   |                      |                                  |                         |                     |                       |
| If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). |                     |   |                      |                                  |                         |                     |                       |
| <b>Total Sheets</b>   | <b>Extra Sheets</b> | <b>Number of each additional 50 or fraction thereof</b> |                      | <b>Fee (\$)</b>                  | <b>Fee Paid (\$)</b>    |                     |                       |
| <hr/>   |                     |   |                      |                                  |                         |                     |                       |
| <b>4. OTHER FEE(S)</b>  |                     |   |                      |                                  |                         |                     |                       |
|   |                     |   |                      |                                  |                         |                     | <b>Fees Paid (\$)</b> |
| Non-English Specification, \$130 fee (no small entity discount)   |                     |   |                      |                                  |                         |                     |                       |
| Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement   |                     |   |                      |                                  |                         |                     | 180.00                |

|                     |                         |                                   |                |
|---------------------|-------------------------|-----------------------------------|----------------|
| <b>SUBMITTED BY</b> |                         |                                   |                |
| Signature           |                         | Registration No. (Attorney/Agent) | 54,408         |
| Name (Print/Type)   | Melissa S. Rones, Ph.D. | Telephone                         | (617) 951-7653 |
|                     |                         | Date                              | 9/19/05        |

|  |   |
|--|---|
| I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. |   |
| Dated: <u>9/19/05</u>  | Signature: <u>Ginny Blundell</u> (Ginny Blundell) |



Application No. (if known): 09/499526

Attorney Docket No.: CIBT-P01-058

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on 9/19/05  
Date

  
Signature

Ginny Blundell

Typed or printed name of person signing Certificate


Registration Number, if applicable

(617) 951-7000

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS by Applicant – Form PTO/SB/08 (79 References)  
References 79, CN2-CN5



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                   |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/B/PTO   |   |    |   | <b>Complete if Known</b> |                   |
|   |   |    |   | Application Number       | 09/499526         |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    |   | Filing Date              | February 10, 2000 |
|   |   |    |   | First Named Inventor     | Kuanghui Lu       |
|   |   |    |   | Art Unit                 | 1647              |
|   |   |    |   | Examiner Name            | R. M. Deberry     |
| Sheet   | 1 | of | 5 | Attorney Docket Number   | CIBT-P01-058      |


| U.S. PATENT DOCUMENTS |                          |  |                                |  |   |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|                       |                          | Number-Kind Code <sup>2</sup> (if known) |                                |  |   |
|                       |                          |  |                                |  |   |

| FOREIGN PATENT DOCUMENTS |                       |   |                  |   |   |                |
|--------------------------|-----------------------|---|------------------|---|---|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T <sup>6</sup> |
|                          |                       | Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) | MM-DD-YYYY       |   |   |                |
|                          |                       |   |                  |   |   |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS |                       |   |  |                |
|---------------------------------|-----------------------|---|--|----------------|
| Examiner Initials               | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.             |  | T <sup>2</sup> |
|                                 | CN2                   | Ando, R.; et al., "Feeding responses to several neuropeptide Y receptor agonists in the neonatal chick," Eur J Pharmacol., 427(1):53-59 (2001).   |  |                |
|                                 | CO2                   | Andres, C. J., et al., "Differentially functionalized diamines as novel ligands for the NPY <sub>2</sub> receptor," Bioorg Med Chem Lett., 13(17):2883-2885 (2003).   |  |                |
|                                 | CP2                   | Bader, R., et al., "Key Motif to Gain Selectivity at the Neuropeptide Y <sub>5</sub> -Receptor: Structure and Dynamics of Micelle-Bound [Ala <sup>31</sup> , Pro <sup>32</sup> ]-NPY," Biochemistry, 41(25):8031-8042 (2002).   |  |                |
|                                 | CQ2                   | Balasubramaniam, A., et al., "Structure-activity studies of peptide YY(22-36): N- $\alpha$ -Ac-[Phe <sup>27</sup> ]PYY(22-36), a potent antisecretory peptide in rat jejunum," Peptides, 14(5):1011-1016 (1993).  |  |                |
|                                 | CR2                   | Balasubramaniam, A., et al., "Synthesis of neuropeptide Y," Int J Pept Protein Res., 29(1):78-83 (1987).  |  |                |
|                                 | CS2                   | Balasubramaniam, A., et al., "Syntheses and Receptor Affinities of Partial Sequences of Peptide YY (PYY)," Peptide Research, 1(1):32-35 (1988).   |  |                |
|                                 | CT2                   | Balasubramaniam, A., et al., "Bis(31/31')[(Cys <sup>31</sup> , Nva <sup>34</sup> ]NPY(27-36)-NH <sub>2</sub> : a neuropeptide Y (NPY) Y <sub>5</sub> receptor selective agonist with a latent stimulatory effect on food intake in rats," Peptides, 23(8):1485-1490 (2002). |  |                |
|                                 | CU2                   | Balasubramaniam, A., "Neuropeptide Y Family of Hormones: Receptor Subtypes and Antagonists," Peptides, 18(3):445-457 (1997).  |  |                |
|                                 | CV2                   | Beck, A., et al., "Highly potent and small neuropeptide Y agonist obtained by linking NPY 1-4 via spacer to $\alpha$ -helical NPY 25-36," FEBS Lett., 244(1):119-122 (1989).  |  |                |
|                                 | CW2                   | Beck-Sickinger, A. G., et al., "Cyclopeptide analogs for characterization of the neuropeptide Y Y <sub>2</sub> -receptor," J Recept Res., 13(1-4):215-228 (1993).   |  |                |
|                                 | CX2                   | Berglund, M. M., et al., "Recent Developments in Our Understanding of the Physiological Role of PP-Fold Peptide Receptor Subtypes," Exp Biol Med (Maywood), 228(3):217-244 (2003).  |  |                |
|                                 | CY2                   | Bischoff, A. and Michel, M. C., "Emerging functions for neuropeptide Y <sub>5</sub> receptors," Trends Pharmacol Sci., 20(3):104-106 (1999).  |  |                |

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                   |
|--|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    |   | <b>Complete If Known</b> |                   |
|  |   |    |   | Application Number       | 09/499526         |
|  |   |    |   | Filing Date              | February 10, 2000 |
|  |   |    |   | First Named Inventor     | Kuanghui Lu       |
|  |   |    |   | Art Unit                 | 1647              |
|  |   |    |   | Examiner Name            | R. M. Deberry     |
|  |   |    |   | Attorney Docket Number   | CIBT-P01-058      |
| Sheet  | 2 | of | 5 |                          |                   |

|     |   |
|-----|---|
| CZ2 | Boublik, J. H., et al., "Synthesis and hypertensive activity of neuropeptide Y fragments and analogues with modified N- or C-termini or D-substitutions," J Med Chem, 32(3):597-601 (1989).   |
| CA3 | Cabrele, C. and Beck-Sickinger, A. G., "Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family," J Pept Sci., 6(3):97-122 (2000).   |
| CB3 | Cabrele, C., et al., "The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats," J Biol Chem., 275(46): 36043-36048 (2000).  |
| CC3 | Cabrele, C., et al., "Ala <sup>31</sup> -Aib <sup>32</sup> : Identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y <sub>5</sub> -receptor," Biochemistry, 41(25):8043-8049 (2002).   |
| CD3 | Cabrele, C., et al., "Y-receptor affinity modulation by the design of pancreatic polypeptide/neuropeptide Y chimera led to Y <sub>5</sub> -receptor ligands with picomolar affinity," Peptides, 22(3):365-378 (2001).   |
| CE3 | Chen, Z., et al., "Ser <sup>13</sup> -phosphorylated PYY from porcine intestine with a potent biological activity," FEBS Lett., 492(1-2):119-122 (2001).  |
| CF3 | Conlon, J. M., "The origin and evolution of peptide YY (PYY) and pancreatic polypeptide (PP)," Peptides, 23(2):269-278 (2002).  |
| CG3 | Corp, E. S., et al., "Feeding after fourth ventricular administration of neuropeptide Y receptor agonists in rats," Peptides, 22(3):493-499 (2001).   |
| CH3 | Cox, H. M., et al., "Structure-activity relationships with neuropeptide Y analogues: a comparison of human Y <sub>1</sub> -, Y <sub>2</sub> - and rat Y <sub>2</sub> -like systems," Regulatory Peptides, 75-76:3-8 (1998).   |
| CI3 | Dumont, Y., et al., "Evaluation of truncated neuropeptide Y analogues with modifications of the tyrosine residue in position 1 on Y <sub>1</sub> , Y <sub>2</sub> and Y <sub>3</sub> receptor sub-types," Eur J Pharmacology, 238(1):37-45 (1993).                      |
| CJ3 | Eto, B., et al., "Effects of Peptide YY and Its Analogues on Chloride Ion Secretion in Fed and Fasted Rat Jejunum," Peptides, 16(8):1403-1409 (1995).   |
| CK3 | Fackelmann, K., "Gut hormone could curb urge to overeat", USA Today.com (Aug 7 2002)  |
| CL3 | Feinstein, R. D., et al., "Structural Requirements for Neuropeptide Y <sup>18-36</sup> -Evoked Hypotension: A Systematic Study," J Med Chem., 35(15):2836-2843 (1992).  |
| CM3 | Fournier, A., et al., "Conformational and Biological Studies of Neuropeptide Y Analogs Containing Structural Alterations," Mol Pharmacol., 45(1):93-101 (1994).   |
| CN3 | Gobbi, M., et al, "Autoradiographic Reevaluation of the Binding Properties of [25I]-[Leu <sup>31</sup> ,Pro <sup>34</sup> ]Peptide YY and [25I]-Peptide YY <sub>3-36</sub> to neuropeptide Y Receptor Subtypes in Rat Forebrain," J Neurochem., 72(4):1663-1670 (1999). |
| CO3 | Gordon, E. A., et al., "Centrally truncated neuropeptide Y analog acts as an agonist for Y <sub>1</sub> receptors on SK-N-MC cells," Neuroscience Letters, 119(2):187-190 (1990).   |
| CP3 | Grundemar, L., et al., "Ligand binding and functional effects of systematic double D-amino acid residue substituted neuropeptide Y analogs on Y <sub>1</sub> and Y <sub>2</sub> receptor types," Regulatory Peptides, 62(2-3):131-136 (1996).                           |
| CQ3 | Halatchev, I. G., et al., "Peptide YY <sub>3-36</sub> Inhibits Food Intake in Mice through a Melanocortin-4 Receptor-Independent Mechanism," Endocrinology, 145(6):2585-2590 (2004).  |
| CR3 | Henry, M., et al., "Energy Metabolic Profile of Mice after Chronic Activation of Central NPY Y <sub>1</sub> , Y <sub>2</sub> , or Y <sub>5</sub> Receptors," Obesity Research 13(1):36-47 (2005).   |
| CS3 | Hu, Y., et al., "Identification of a Novel Hypothalamic Neuropeptide Y Receptor Associated with Feeding Behavior," J Biol Chem., 271(42):26315-26319 (1996).  |
| CT3 | Inui, A., "Neuropeptide Y feeding receptors: are multiple subtypes involved?" Trends Pharmacol Sci., 20(2):43-46 (1999).  |
| CU3 | Kanatani, A., et al., "L-152,804: Orally active and selective neuropeptide Y Y <sub>5</sub> receptor antagonist," Biochemical Biophysical Research Communications, 272(1):169-173 (2000).   |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

|  |   |    |   |                          |                   |
|--|---|----|---|--------------------------|-------------------|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |                   |
|  |   |    |   | Application Number       | 09/499526         |
|  |   |    |   | Filing Date              | February 10, 2000 |
|  |   |    |   | First Named Inventor     | Kuanghui Lu       |
|  |   |    |   | Art Unit                 | 1647              |
|  |   |    |   | Examiner Name            | R. M. Deberry     |
| Sheet  | 3 | of | 5 | Attorney Docket Number   | CIBT-P01-058      |

|     |  |
|-----|--|
| CV3 | Kanatani, A., et al., "The novel neuropeptide Y Y <sub>1</sub> receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability," <i>Biochem Biophys Res Commun.</i> , 266(1):88-91 (1999).  |
| CW3 | Keire, D. A., et al., "Structure and receptor binding of PYY analogs," <i>Peptides</i> , 23(2):305-321 (2002).   |
| CX3 | Keire, D. A., et al., "Solution structure of monomeric peptide YY supports the functional significance of the PP-fold," <i>Biochemistry</i> , 39(32):9935-9942 (2000).   |
| CY3 | Keire, D. A., et al., "Primary structures of PYY, [Pro <sup>34</sup> ] PYY, and PYY-(3-36) confer different conformations and receptor selectivity," <i>Am J Physiol. Gastrointest Liver Physiol.</i> , 279(1):G126-G131 (2000).                                       |
| CZ3 | Kirby, D. A., et al., "Neuropeptide Y: Y <sub>1</sub> and Y <sub>2</sub> affinities of the complete series of analogues with single D-residue substitutions," <i>J Med Chem.</i> , 36(24):3802-3808 (1993).  |
| CA4 | Kirby, D. A., et al., "Y <sub>1</sub> and Y <sub>2</sub> receptor selective neuropeptide Y analogues: evidence for a Y <sub>1</sub> receptor subclass," <i>J Med Chem.</i> , 38(22):4579-4586 (1995).  |
| CB4 | Krstenansky, J. L., et al., "Centrally truncated and stabilized porcine neuropeptide Y analogs: design, synthesis, and mouse brain receptor binding," <i>Proc Natl Acad Sci U S A.</i> , 86(12):4377-4381 (1989).  |
| CC4 | Krstenansky, J. L., et al., "C-terminal modifications of neuropeptide Y and its analogs leading to selectivity for the mouse brain receptor over the porcine spleen receptor," <i>Neuropeptides</i> , 17(3):117-120 (1990).  |
| CD4 | Leban, J. J., et al., "Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y <sub>2</sub> -type receptors and potent functional antagonism at a Y <sub>1</sub> -type receptor," <i>J Med Chem.</i> , 38(7):1150-1157 (1995).            |
| CE4 | Liu, C. D., et al., "Synthetic peptide YY analog binds to a cell membrane receptor and delivers fluorescent dye to pancreatic cancer cells," <i>J Gastrointest Surg.</i> , 5(2):147-152 (2001).  |
| CF4 | Lundell, I., et al., "Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY," <i>J Biol Chem.</i> , 270(49):29123-29128 (1995).  |
| CG4 | Makimura, H., et al., Obesity Poster Abstract No. 118 "Adrenalectomy stimulates hypothalamic Proopiomelanocortin mRNA but does not correct obesity in diet-induced obese mice."  |
| CH4 | Markison S., et al., Obesity Poster Abstract No. 119 "Selective melanin-concentrating hormone receptor antagonists decrease feeding in rodents."   |
| CI4 | Martin, N. M., et al., "Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY <sub>3-36</sub> but resistant to ghrelin," <i>Int J Obes Relat Metab Disord.</i> , 28(7):886-893 (2004).  |
| CJ4 | Mashiko, S., et al., "Characterization of neuropeptide Y (NPY) Y <sub>5</sub> receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp <sup>34</sup> NPY," <i>Endocrinology</i> , 144(5):1793-1801 (2003).                                 |
| CK4 | Mashiko, S., et al., Obesity Poster Abstract No. 120 "Characterization of neuropeptide Y Y <sub>5</sub> receptor mediated obesity in mice"   |
| CL4 | Mullins, D., et al., "Identification of potent and selective neuropeptide Y Y <sub>1</sub> receptor agonists with orexigenic activity in vivo," <i>Molecular Pharmacology</i> , 60(3):534-540 (2001).  |
| CM4 | Murakami, Y., et al., "1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y <sub>1</sub> receptor antagonists," <i>J Med Chem.</i> , 42(14):2621-2632 (1999).   |
| CN4 | Murase, S., et al., "Acylation of the $\alpha$ -amino group in neuropeptide Y(12-36) increases binding affinity for the Y <sub>2</sub> receptor," <i>J Biochem (Tokyo)</i> , 119(1):37-41 (1996).  |
| CO4 | Parker, E. M., et al., "GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y <sub>1</sub> receptor antagonists and neuropeptide Y Y <sub>4</sub> receptor agonists," <i>Eur J Pharmacol.</i> , 349(1):97-105 (1998). |
| CP4 | Parker, E. M., et al., "[D-Trp <sup>34</sup> ] neuropeptide Y is a potent and selective neuropeptide Y Y <sub>5</sub> receptor agonist with dramatic effects on food intake," <i>Peptides</i> , 21(3):393-399 (2000).  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

|  |   |    |   |                          |                   |
|--|---|----|---|--------------------------|-------------------|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |                   |
|  |   |    |   | Application Number       | 09/499526         |
|  |   |    |   | Filing Date              | February 10, 2000 |
|  |   |    |   | First Named Inventor     | Kuanghui Lu       |
|  |   |    |   | Art Unit                 | 1647              |
|  |   |    |   | Examiner Name            | R. M. Deberry     |
| Sheet  | 4 | of | 5 | Attorney Docket Number   | CIBT-P01-058      |

|     |  |
|-----|--|
| CQ4 | Parker, S. L. and Parker, M. S., "FMRFamides exert a unique modulation of rodent pancreatic polypeptide sensitive neuropeptide Y (NPY) receptors," Can J Physiol Pharmacol., 78(2):150-161 (2000).   |
| CR4 | Potter, E. K., et al., "A novel neuropeptide Y analog, N-acetyl [Leu <sup>28</sup> ,Leu <sup>31</sup> ]neuropeptide Y-(24-36), with functional specificity for the presynaptic (Y <sub>2</sub> ) receptor," Eur J Pharmacol., 267(3):253-262 (1994).   |
| CS4 | Renshaw, D. and Batterham, R. L., "Peptide YY: A Potential Therapy for Obesity," Curr Drug Targets, 6(2):171-179 (2005).   |
| CT4 | Rico, L., et al., Obesity Poster Abstract No. 117 "Early and dissociated leptin and insulin resistance in transgenic mice overexpressing leptin from keratinocytes."   |
| CU4 | Rist, B., et al., "The bioactive conformation of neuropeptide Y analogues at the human Y <sub>2</sub> -receptor," Eur J Biochem., 247(3):1019-1028 (1997).   |
| CV4 | Rist, B., et al., "Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y <sub>2</sub> receptor," FEBS Lett., 394(2):169-173 (1996).  |
| CW4 | Sato, N., et al., "Design and Synthesis of the Potent, Orally Available, Brain-Penetrable Arylpyrazole Class of Neuropeptide Y <sub>5</sub> Receptor Antagonists," J Med Chem., 46(5):666-669 (2003).  |
| CX4 | Servin, A. L., et al., "Peptide-YY and Neuropeptide-Y Inhibit Vasoactive Intestinal Peptide-Stimulated Adenosine 3',5'-Monophosphate Production in Rat Small Intestine: Structural Requirements of Peptides for Interacting with Peptide-YY-Preferring Receptors," Endocrinology, 124(2):692-700 (1989). |
| CY4 | Shan, L., et al., "Structural Basis for Gluten Intolerance in Celiac Sprue," Science, 297(5590):2275-2279 (2002).  |
| CZ4 | Sheikh, S. P., "Neuropeptide Y and peptide YY: major modulators of gastrointestinal blood flow and function," Am J Physiol., 261(5 Pt 1):G701-G715 (1991).   |
| CA5 | Silva, A. P., et al., "Neuropeptide Y and its receptors as potential therapeutic drug targets," Clinica Chimica Acta, 326(1-2):3-25 (2002).  |
| CB5 | Small, C. J., et al., "Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release," Proc Natl Acad Sci U S A., 94(21):11686-11691 (1997).   |
| CC5 | Soll, R. M., et al., "Novel analogues of neuropeptide Y with a preference for the Y <sub>1</sub> -receptor," Eur J Biochem., 268(10):2828-2837 (2001).   |
| CD5 | Tatemoto, K., et al., "Synthesis of receptor antagonists of neuropeptide Y," Proc Natl Acad Sci U S A., 89(4):1174-1178 (1992).  |
| CE5 | Thum, A., et al., "Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4," Exp Clin Endocrinol Diabetes, 110(3):113-118 (2002).   |
| CF5 | Totheroh, G., "Science Offers Promising Treatment for an Overweight Nation" CBN News (Sept 4, 2003).   |
| CG5 | Tschop, M., et al., "Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature. 2004 Jul 8; 430(6996):1 p following 165; discussion 2 p following 165.  |
| CH5 | Tseng, W. W. and Liu, C. D., "Peptide YY and cancer: current findings and potential clinical applications," Peptides, 23(2):389-395 (2002).  |
| CI5 | Turnbull, A. V., et al., "Selective antagonism of the NPY Y <sub>5</sub> receptor does not have a major effect on feeding in rats," Diabetes, 51(8):2441-2449 (2002).  |
| CJ5 | Walker, M. W., et al., "Neuropeptide Y modulates neurotransmitter release and Ca <sup>2+</sup> currents in rat sensory neurons," J Neurosci., 8(7):2438-2446 (1988).   |
| CK5 | Walker, M. W., et al., "A structure-activity analysis of the cloned rat and human Y <sub>4</sub> receptors for pancreatic polypeptide," Peptides, 18(4):609-612 (1997).  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|





PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                   |
|--|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    |   | <b>Complete if Known</b> |                   |
|  |   |    |   | Application Number       | 09/499526         |
|  |   |    |   | Filing Date              | February 10, 2000 |
|  |   |    |   | First Named Inventor     | Kuanghui Lu       |
|  |   |    |   | Art Unit                 | 1647              |
|  |   |    |   | Examiner Name            | R. M. Deberry     |
| Sheet  | 5 | of | 5 | Attorney Docket Number   | CIBT-P01-058      |

|  |     |   |  |
|--|-----|---|--|
|  | CL5 | Weinberg, D. H., et al., "Cloning and expression of a novel neuropeptide Y receptor," J Biol Chem., 271(28):16435-16438 (1996). |  |
|  | CM5 | Wilding, J. P., "Neuropeptides and appetite control," Diabet Med., 19(8):619-627 (2002).  |  |
|  | CN5 | HYPERDICTIONARY definition of "Structure Activity Relationship"   |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|